Jim Winkler, Ph.D.

Head of Degrader Technologies

“Logic will get you from A to Z; imagination will get you everywhere.”

– Albert Einstein

Jim Winkler is Frontier Medicines’ Head of Degrader Technologies and has spent nearly 40 years in the field of drug discovery and development, with expertise spanning target validation and early drug discovery through to translational medicine and clinical development. Previously, Jim was the Chief Scientific Officer of Arvinas, where he led the development of its targeted protein degradation technology and built a growing preclinical pipeline of degraders.

Jim has served as VP of Discovery Biology and Translational Biology at Array Therapeutics, where he oversaw 16 compounds from drug discovery into clinical development. Several of these compounds have progressed to become marketed drugs and others have delivered successful Phase 2 and Phase 3 clinical trials. Jim has also served as VP of Discovery and Translational Biology at Forma Therapeutics. He began his scientific career in big pharma, including J&J, GSK and SmithKline Beecham.

Jim did his postdoctoral training at SmithKline Beecham and received his Ph.D. in Pharmacology at the Medical College of Pennsylvania and his A.B. in Biochemistry from Princeton University.